Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.

C. Barrientos, Jacqueline; R. Furman, Richard; P. Leonard, John; W. Flinn, Ian; Roop, Kanti; de Vos, Sven; T. Schreeder, Marshall; D. Wagner‐Johnston, Nina; P. Sharman, Jeff; E. Boyd, Thomas; Fowler, Nathan; Holes, Leanne; M. Johnson, David; Li, Daniel; Dansey, Roger; M. Jahn, Thomas; Coutré, Steven

doi:10.1200/jco.2013.31.15_suppl.7017

Public

Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.

Published in Journal of Clinical Oncology • May 20, 2013

Authors:

Jacqueline C. Barrientos

Richard R. Furman

John P. Leonard

Abstract

7017 Background: PI3K-delta signaling is critical for proliferation, survival, homing and tissue retention of malignant B cells. Idelalisib is a first-in-class, selective, oral inhibitor of PI3Kδ that has shown considerable monotherapy activity in pts with heavily pretreated CLL. Methods: This phase...

Subject

Idelalisib

Medicine

Bendamustine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!